Marvel Biosciences announced that Dr. Jérôme Becker will present research on Adenosine A2A receptors as a therapeutic target for autism at the European Purine Meeting in France. The company's lead drug candidate, MB-204, an A2A receptor antagonist, has shown promising preclinical results in improving social interaction in autism models. Marvel supports the conference as a gold sponsor and is progressing toward Phase 1 clinical trials for MB-204, aiming to address autism and related neurological disorders. This presentation and ongoing research highlight the potential of MB-204 to become a novel treatment option for autism spectrum disorders.
Micron Technology's stock fell nearly 5% in premarket trading after a strong earnings report that saw its revenue quadruple year-over-year to $41.46 billion. Despite this, investors are cautious due to rising costs associated with building AI infrast...
Marvell Technology's stock has surged over 220% since last September, driven by strong growth in its data center business which now accounts for 76% of total revenue. The company expects its interconnect business to grow 70% in fiscal year 2027 and c...
The ROBO Global Robotics and Automation Index (ROBO) and the ROBO Global Artificial Intelligence Index (THNQ) recently rebalanced their portfolios to emphasize AI backbone hardware and physical automation. THNQ added semiconductor firms Marvell Techn...
Marvell Technology's stock surged from $84.88 to $276.70 in 2026, driven by strong AI infrastructure demand and a robust Q1 earnings report showing 27.6% revenue growth. The company expects continued growth with a price target of $306.71, implying a ...
Marvell Technology's CFO, Daniel Durn, sold 2,250 shares on June 23, cashing out around $632,272 as the stock price hovered near $281. This sale represents about 25% of his initial investment, signaling potential exhaustion in the stock's strong rall...
